Clinical Trials Logo

Hemorrhagic Stroke clinical trials

View clinical trials related to Hemorrhagic Stroke.

Filter by:

NCT ID: NCT05502874 Not yet recruiting - Hemorrhage Clinical Trials

Multicenter Registry for Assessment of Markers of Early Neurological Deterioration in Primary Intracerebral Hemorrhage

CATCH
Start date: September 1, 2022
Phase:
Study type: Observational

This multicenter observational study will explore the risk factors of early neurological deterioration(END) in patients with primary and to investigate the association between END and outcome.

NCT ID: NCT05491824 Recruiting - Stroke Clinical Trials

Bio-Repository of DNA in Stroke: an Epidemiological and Genetic Study

BRAINS
Start date: June 11, 2005
Phase:
Study type: Observational

The Bio-Repository of DNA in Stroke (BRAINS) recruits all subtypes of stroke as well as controls from two different continents, Europe and Asia. Subjects recruited from the United Kingdom (UK) will include stroke patients of European ancestry as well as British South Asians. Stroke subjects from South Asia will be recruited from India and Sri Lanka. Subjects are also recruited in Qatar. South Asian cases will also have control subjects recruited.

NCT ID: NCT05440682 Recruiting - Clinical trials for Traumatic Brain Injury

Connectivity in Cranioplasty

Start date: October 27, 2020
Phase: N/A
Study type: Interventional

An Exploratory Interventional study to assess the effects of cranioplasty on brain network connectivity, neuropsychological and motor functioning in patients with severe acquired brain injury with pre-, post-cranioplasty and 6 months follow-up assessments.

NCT ID: NCT05419193 Recruiting - Stroke Clinical Trials

PROpranolol for Cerebral Hemorrhage-ASsociated pnEumonia (PRO-CHASE)

PRO-CHASE
Start date: February 21, 2023
Phase: Phase 2
Study type: Interventional

Stroke-associated pneumonia (SAP) is a grave complication of stroke and one of the most important predictors for patients' poor outcomes. Stroke associated pneumoniaSAP and other infections limited the overall efficacy of stroke management. Increasing evidence suggests that sympathetic nervous system activity contributes to post post-stroke immunosuppression and emergence of infections. This study is designed to test the safety and efficacy of an adrenergic β receptor blocker propranolol in reducing SAP in hemorrhagic stroke patients, in a multi-center, randomized, open-labeled, end point-blinded, trial.

NCT ID: NCT05416619 Completed - Stroke Clinical Trials

Effects of Hand MOtor Rehabilitation Using a sEMG-biofeedback

MORE
Start date: August 14, 2017
Phase: N/A
Study type: Interventional

Stroke is the first cause of disability worldwide. The motor impairment of the hand is one of the most common sequelae in patients after stroke. Indeed, approximately 60% of patients with diagnosis of stroke suffers from hand sensorimotor impairment. In the last years, new approaches in neurorehabilitation field has been permitted to enhance hand motor recovery. Wearable devices permit to apply sensors to the patient's body for monitoring the kinematic and dynamic characteristics of patient's motion. Moreover, wearable sensors combined with electrodes detecting muscle activation (i.e. surface electromyography - sEMG) permit to provide biofeedback to the patient to improve motor recovery.

NCT ID: NCT05397106 Recruiting - Brain Tumor Clinical Trials

Post Market Clinical Follow-up of CODMAN CERTAS Programmable Valve

Start date: January 24, 2023
Phase:
Study type: Observational

Post-Market Clinical Follow-up Registry of Patients with CODMAN CERTAS Plus Programmable Valves.

NCT ID: NCT05338697 Recruiting - Stroke Clinical Trials

Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials

VERIFY
Start date: June 18, 2022
Phase:
Study type: Observational

VERIFY will validate biomarkers of upper extremity (UE) motor outcome in the acute ischemic stroke window for immediate use in clinical trials, and explore these biomarkers in acute intracerebral hemorrhage. VERIFY will create the first multicenter, large-scale, prospective dataset of clinical, transmagnetic stimulation (TMS), and MRI measures in the acute stroke time window.

NCT ID: NCT05300997 Recruiting - Atrial Fibrillation Clinical Trials

Translational Immunodiagnostics in Stroke (TrImS)

TrImS
Start date: May 1, 2022
Phase:
Study type: Observational [Patient Registry]

In adult patients presenting to emergency departments within 24 hours of symptom onset with suspected acute stroke, we aim: 1. to identify early brain- and pathology-specific circulating, whole blood, plasma and serum panorOmic biomarkers that enable early acute stroke detection, diagnosis, dynamics, differentiation, monitoring, prediction and prognosis. 2. to identify early brain- and pathology-specific, panorOmic biomarkers in saliva that enable early acute stroke detection, diagnosis, dynamics, differentiation, monitoring, prediction and prognosis. 3. to derive biomarker platforms of models for early acute stroke detection, diagnosis, dynamics, differentiation, monitoring, prediction and prognosis 4. to validate these models in independent and external datasets

NCT ID: NCT05268861 Not yet recruiting - Clinical trials for Cognitive Impairment

The Role of Cognition in Motor Learning After Stroke

Start date: April 2022
Phase: N/A
Study type: Interventional

Stroke leads to lasting problems in using the upper limb (UL) for everyday life activities. While rehabilitation programs depend on motor learning, UL recovery is less than ideal. Implicit learning is thought to lead to better outcomes than explicit learning. Cognitive factors (e.g., memory, attention, perception), essential to implicit motor learning, are often impaired in people with stroke. The objective of this study is to investigate the role of cognitive deficits on implicit motor learning in people with stroke. The investigators hypothesize that 1) subjects with stroke will achieve better motor learning when training with additional intrinsic feedback compared to those who train without additional intrinsic feedback, and 2) individuals with stroke who have cognitive deficits will have impairments in their ability to use feedback to learn a motor skill compared to individuals with stroke who do not have cognitive deficits. A recent feedback modality, called error augmentation (EA), can be used to enhance motor learning by providing subjects with magnified motor errors that the nervous system can use to adapt performance. The investigators will use a custom-made training program that includes EA feedback in a virtual reality (VR) environment in which the range of the UL movement is related to the patient's specific deficit in the production of active elbow extension. An avatar depiction of the arm will include a 15 deg elbow flexion error to encourage subjects to increase elbow extension beyond the current limitations. Thus, the subject will receive feedback that the elbow has extended less than it actually has and will compensate by extending the elbow further. Subjects will train for 30 minutes with the EA program 3 times a week for 9 weeks. Kinematic and clinical measures will be recorded before, after 3 weeks, after 6 weeks, and after 9 weeks. Four weeks after the end of training, there will be a follow-up evaluation. Imaging scans will be done to determine lesion size and extent, and descending tract integrity with diffusion tensor imaging (DTI). This study will identify if subjects with cognitive deficits benefit from individualized training programs using enhanced intrinsic feedback. The development of treatments based on mechanisms of motor learning can move rehabilitation therapy in a promising direction by allowing therapists to design more effective interventions for people with problems using their upper limb following a stroke.

NCT ID: NCT05255809 Recruiting - Clinical trials for Chronic Hemorrhagic Stroke

Alexander Technique, Routine Physical Therapy, Balance, Posture, Functional Mobility , Chronic, Hemorrhagic, Stroke

Start date: December 28, 2021
Phase: N/A
Study type: Interventional

MATERIALS AND METHODS Design: The randomized controlled trial. Setting: Nusrat Abdul Rauf Centre for Enablement, Faisalabad. Sample size:40 in each group. Experimental group: Recieve Alexander Technique with Routine Physical Therapy. Control Group: Recieve Routine Physical Therapy.